Loading
A phase 3 trial of Tamoxifen and Toremifene in Breast cancer, run by Chinese Anti-Cancer Association, with a status the registry has not verified recently.
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer is a phase 3 interventional study registered as NCT03351062 by Chinese Anti-Cancer Association, with 844 participants planned, started 2017-11 and due to reach its primary completion in 2025-12. Interventions recorded: Tamoxifen, Toremifene. Conditions recorded: Breast Cancer Female.
Linked to the drug Toremifene because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toremifene, Breast cancer (all types) and the tag pipeline.
Shares Toremifene and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen and the tag pipeline.
Shares Tamoxifen and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/